Difference between revisions of "Malignant mesothelioma"

Jump to navigation Jump to search
no edit summary
 
(6 intermediate revisions by the same user not shown)
Line 8: Line 8:
| LMDDx      = mesothelial hyperplasia, [[fibrosing pleuritis]], [[adenocarcinoma]] - esp. [[lung adenocarcinoma|lung]], [[serous carcinoma]]
| LMDDx      = mesothelial hyperplasia, [[fibrosing pleuritis]], [[adenocarcinoma]] - esp. [[lung adenocarcinoma|lung]], [[serous carcinoma]]
| Stains    =  
| Stains    =  
| IHC        = calretinin +ve, D2-40 +ve, [[CK5/6]] +ve, WT-1 +ve, [[CK7]] +ve, CEA -ve, [[TTF-1]] -ve
| IHC        = calretinin +ve, D2-40 +ve, [[CK5/6]] +ve, WT-1 +ve, [[CK7]] +ve, CEA -ve, [[TTF-1]] -ve, MTAP -ve (pleural mesothelioma), BAP1 -ve
| EM        =
| EM        =
| Molecular  = +/-p16 deletion
| Molecular  = +/-p16 deletion
Line 30: Line 30:
'''Malignant mesothelioma''', also '''mesothelioma''', is a form of [[cancer]]. It arises from the mesothelium.  
'''Malignant mesothelioma''', also '''mesothelioma''', is a form of [[cancer]]. It arises from the mesothelium.  


It should '''not''' be confused with ''[[benign multicystic mesothelioma]]'' and ''[[benign papillary mesothelioma]]''.
It should '''not''' be confused with ''[[benign multicystic mesothelioma]]'' and ''[[well-differentiated papillary mesothelial tumour]]'' (previously ''benign papillary mesothelioma'').


==General==
==General==
Line 128: Line 128:


Note:
Note:
*The above are ''not'' very useful in individual cases.
*A simple pankeratin is useful for seeing where epithelial cells are.
*A simple pankeratin is useful for seening where epithelial cells are.
 
Others:
*MTAP -ve.<ref name=pmid34465883>{{cite journal |authors=Dacic S |title=Pleural mesothelioma classification-update and challenges |journal=Mod Pathol |volume=35 |issue=Suppl 1 |pages=51–56 |date=January 2022 |pmid=34465883 |doi=10.1038/s41379-021-00895-7 |url=}}</ref>
**May not be sensitive and specific for peritoneal mesothelioma.{{fact}}


===Mesothelioma versus adenocarcinoma===
===Mesothelioma versus adenocarcinoma===
Line 141: Line 144:
**D2-40.
**D2-40.
**[[CK5/6]].
**[[CK5/6]].
**[[CA-125]].<ref name=pmid9023557>{{cite journal |authors=Bateman AC, al-Talib RK, Newman T, Williams JH, Herbert A |title=Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression |journal=Histopathology |volume=30 |issue=1 |pages=49–56 |date=January 1997 |pmid=9023557 |doi=10.1046/j.1365-2559.1996.d01-562.x |url=}}</ref>
*Carcinoma markers:
*Carcinoma markers:
**CEA (monoclonal and polyclonal).
**CEA (monoclonal and polyclonal).
**[[TTF-1]].
**[[TTF-1]].
**[[Ber-EP4]].
**[[Ber-EP4]].
***100% of lung adenocarcinoma versus ~25% of mesotheliomas.<ref>{{cite journal |authors=Ordóñez NG |title=Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature |journal=Am J Clin Pathol |volume=109 |issue=1 |pages=85–9 |date=January 1998 |pmid= |doi=10.1093/ajcp/109.1.85 |url=}}</ref>
**MOC-31.
**MOC-31.
**CD15.
**CD15.
Line 156: Line 161:
*[[CD138]] +ve.
*[[CD138]] +ve.
**Usually -ve in mesothelioma.<ref name=pmid12866374>{{Cite journal  | last1 = Chu | first1 = PG. | last2 = Arber | first2 = DA. | last3 = Weiss | first3 = LM. | title = Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases. | journal = Am J Clin Pathol | volume = 120 | issue = 1 | pages = 64-70 | month = Jul | year = 2003 | doi = 10.1309/48KC-17WA-U69B-TBXQ | PMID = 12866374 }}</ref>
**Usually -ve in mesothelioma.<ref name=pmid12866374>{{Cite journal  | last1 = Chu | first1 = PG. | last2 = Arber | first2 = DA. | last3 = Weiss | first3 = LM. | title = Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases. | journal = Am J Clin Pathol | volume = 120 | issue = 1 | pages = 64-70 | month = Jul | year = 2003 | doi = 10.1309/48KC-17WA-U69B-TBXQ | PMID = 12866374 }}</ref>
*MTAP -ve.<ref name=pmid34465883>{{cite journal |authors=Dacic S |title=Pleural mesothelioma classification-update and challenges |journal=Mod Pathol |volume=35 |issue=Suppl 1 |pages=51–56 |date=January 2022 |pmid=34465883 |doi=10.1038/s41379-021-00895-7 |url=}}</ref>
**May not be sensitive and specific for peritoneal mesothelioma.{{fact}}


==Molecular==
==Molecular==
49,277

edits

Navigation menu